吉林敖東(000623.SZ):延吉藥業獲得“抗感解毒顆粒”、“生脈顆粒”的藥品補充申請批準通知書
格隆匯4月10日丨吉林敖東(000623.SZ)公佈,近日,吉林敖東藥業集團股份有限公司控股子公司吉林敖東藥業集團延吉股份有限公司(簡稱“延吉藥業”)收到國家藥品監督管理局下發的“抗感解毒顆粒”、“生脈顆粒”的《藥品補充申請批準通知書》。
本次公司控股子公司延吉藥業獲得《藥品補充申請批準通知書》的“抗感解毒顆粒”、“生脈顆粒”,系從吉林省德商藥業股份有限公司購入的中藥品種,進一步增加公司產品種類,增強了公司核心競爭力,爲公司穩步發展創造了有利條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.